Results 201 to 210 of about 7,313,278 (356)
Molecular Oncology, EarlyView.Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi +12 more
wiley +1 more source
27-Hydroxycholesterol in cancer development and drug resistance. [PDF]
J Enzyme Inhib Med ChemHou Y +5 more
europepmc +1 more source
EPISOME-MEDIATED TRANSFER OF DRUG RESISTANCE IN ENTEROBACTERIACEAE VII [PDF]
, 1964 Tsutomu Watanabe +4 more
openalex +1 more source
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs
Molecular Oncology, EarlyView.In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza +3 more
wiley +1 more source
Fast evolution of SOS-independent multi-drug resistance in bacteria. [PDF]
ElifeZhang L +9 more
europepmc +1 more source
DRUG RESISTANCE OF ENTERIC BACTERIA IV [PDF]
, 1964 EIKO KONDO, Susumu Mitsuhashi
openalex +1 more source
Molecular Oncology, EarlyView.Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
Evolution of Antiviral Drug Resistance in SARS-CoV-2. [PDF]
VirusesDinata R, Baindara P, Mandal SM.
europepmc +1 more source